Case Report: Extravazation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin®): A Case Report-Reference-Cited by-同舟云学术

Case Report: Extravazation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin®): A Case Report

Published:2006-04 Issue:2 Volume:21 Page:101-105
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Williams Gethin¹,Palmer Matthew R.¹,Parker J. Anthony¹,Joyce Robin²

Affiliation:

1. Nuclear Medicine, Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA.

2. Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2006.21.101

Reference32 articles.

1. Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin)

2. Radiation Safety Guidelines for Radioimmunotherapy With Yttrium 90 Ibritumomab Tiuxetan

3. Extravasation of systemic hemato-oncological therapies

4. Skin necrosis from extravasation of Vinorelbine*

5. Evaluation and Treatment of Chemotherapy Extravasation Injuries

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extravasation of brentuximab vedotin, an antibody-drug conjugate, in a patient with anaplastic large cell lymphoma;European Journal of Hospital Pharmacy;2024-03-06

2. Active monitoring improves radiopharmaceutical administration quality;Frontiers in Nuclear Medicine;2023-03-07

3. The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy;Journal of Cutaneous Pathology;2022-10-03

4. Practical Tools for Patient-specific Characterization and Dosimetry of Radiopharmaceutical Extravasation;Health Physics;2022-07-15

5. 177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT;EJNMMI Physics;2022-05-03